Intuitive Surgical (NASDAQ:ISRG) Price Target Increased to $375.00 by Analysts at Jefferies Financial Group

Intuitive Surgical (NASDAQ:ISRG) had its target price lifted by Jefferies Financial Group from $365.00 to $375.00 in a report issued on Friday, Benzinga reports. They currently have a hold rating on the medical equipment provider’s stock.

A number of other research analysts have also issued reports on ISRG. StockNews.com lowered shares of Intuitive Surgical from a buy rating to a hold rating in a research note on Thursday, February 29th. Barclays boosted their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an overweight rating in a research note on Thursday, January 25th. Royal Bank of Canada boosted their price objective on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an outperform rating in a report on Wednesday, January 24th. Citigroup boosted their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a buy rating in a report on Wednesday, April 3rd. Finally, Stifel Nicolaus boosted their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a buy rating in a report on Monday, April 8th. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $396.17.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $366.34 on Friday. Intuitive Surgical has a one year low of $254.85 and a one year high of $403.76. The firm’s fifty day moving average is $386.84 and its two-hundred day moving average is $343.10. The firm has a market cap of $129.85 billion, a PE ratio of 66.13, a P/E/G ratio of 5.78 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 13.27%. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same period in the previous year, the business posted $1.00 earnings per share. The business’s revenue was up 11.5% compared to the same quarter last year. Research analysts predict that Intuitive Surgical will post 4.93 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In related news, CEO Gary S. Guthart sold 24,325 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at $3,544,365.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Gary S. Guthart sold 24,325 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the completion of the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at $3,544,365.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $370.20, for a total transaction of $740,400.00. Following the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,373,093.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 248,418 shares of company stock valued at $95,927,097. Company insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Several large investors have recently made changes to their positions in the business. RB Capital Management LLC grew its holdings in Intuitive Surgical by 4.4% during the 1st quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $523,000 after purchasing an additional 73 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Intuitive Surgical by 0.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock valued at $285,603,000 after acquiring an additional 5,233 shares during the last quarter. Baird Financial Group Inc. boosted its stake in Intuitive Surgical by 2.3% during the 1st quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock valued at $6,362,000 after acquiring an additional 481 shares during the last quarter. Brown Brothers Harriman & Co. boosted its stake in Intuitive Surgical by 576.7% during the 1st quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock valued at $122,000 after acquiring an additional 346 shares during the last quarter. Finally, Covestor Ltd boosted its stake in Intuitive Surgical by 50.4% during the 1st quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock valued at $126,000 after acquiring an additional 140 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.